Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Group Leads $20 Million Round for Israel’s Biomica, a Microbiome Company

publication date: Dec 21, 2022

Israel’s Biomica, a clinical-stage microbiome biopharma, signed a $20 million funding agreement led by Shanghai Healthcare Capital (SHC), a fund managed by SIIC Capital with Shanghai Pharma one of the founding Limited Partners. Biomica will use the capital to complete a Phase I trial of its lead candidate and prepare a second candidate for clinical trials. The company is developing microbiome therapies for antibiotic resistant bacteria, immuno-oncology and gastrointestinal disorders. Biomica develops microbiome-based therapeutics using its Computational Predictive Biology platform (CPB), licensed from its corporate parent, Evogene. More details...

Stock Symbol: (NSDQ: EVGN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital